David Green tells MassDevice.com about the decision to split Harvard Bioscience and Harvard Apparatus Regenerative Technology, his choice to move over to the new entity and why regenerative technologies are poised to transform medicine.
Medtech veteran Dave Johnson has been with Alliqua Biomedical for less than 2 years, during which time he's overseen a major hiring spree, 3 business development deals and the company's 1st acquisition. In an interview with MassDevice.com, Johnson talks about his step-by-step perspective and where he hopes Alliqua will be in 5 years.
Tengion puts itself and its organ regeneration technology on the auction block, hiring Jefferies LLC to explore "strategic alternatives."
Tengion, TNGN, Jefferies, organ regeneration, kidney
Tengion (NSDQ:TNGN) said it's hired Jefferies to assess "all strategic alternatives," corporate shorthand for putting the Winston-Salem, N.C.-based company and its organ regeneration technology on the auction block.
Despite the widespread skepticism over renal denervation for hypertension after the failure of Medtronic's Symplicity-3 trial, St. Jude Medical could be poised to snatch victory from the jaws of defeat with its next-generation EnligHTN device.
Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
Payments from pharmaceutical companies touch hundreds of thousands of doctors. The 17 companies we've tracked spent $1.4 billion in 2013 alone. Here are our top five takeaways from following all that money.
by Charles Ornstein, Eric Sagara and Ryann Grochowski Jones, ProPublica